Octapharma

Focus: Octapharma is a Vienna-based specialty pharma company focused on plasma-derived products for rare diseases and immunodeficiency, with 5,000+ employees and a established commercial footprint.

Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES A

Employees

5000+

Open Jobs

About Octapharma

AI assessmentNot Hiring

No open roles listed right now. Follow Octapharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Late-stage

14 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

Panzyga

Primary Immunodeficiency, Immune Thrombocytopenic Purpura, Multifocal Motor Neuropathy

$34M Part D

Peak

Flagship product driving 95% of company revenue; established franchise with multiple approved indications but facing lifecycle maturity risk.

Help build intelligence for Octapharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established, cash-generative business with Panzyga ($34M Part D spending) providing revenue stability and reinvestment capacity for pipeline expansion
Deep pipeline of 100+ programs across rare bleeding disorders, immunodeficiency, and emerging indications with 21 Phase 3 trials ongoing—substantial clinical development activity
European-headquartered specialty pharma with 5,000+ employees offering scale and resources without mega-pharma bureaucracy; focused therapeutic area (plasma products, rare diseases) enables targeted expertise development

Watch Out For

Extreme revenue concentration (95% Panzyga) creates single-product dependency risk; Panzyga at peak lifecycle with approaching LOE on supporting products (Albumin, Octagam) threatens future growth
No active job postings and limited hiring visibility suggests constrained near-term headcount growth; unclear H1B sponsorship and private funding status raise compensation and visa support questions
Heavy reliance on plasma-derived products exposes company to supply chain volatility, regulatory shifts in plasma collection, and competition from recombinant alternatives currently in Phase 3 (e.g., Human-cl rhFVIII)

Pipeline & Clinical Trials

Octaplas

Thrombotic Thrombocytopenic Purpura

N/A

Clinical Trials (1)

NCT01938404Octaplas Adult TTP Trial

N/A

A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintena

Renal Transplant Recipients With Anti-HLA Antibodies

N/A

Clinical Trials (1)

NCT02115503A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintenance Therapy in Alloantibody Positive Renal Allograft Recipients

N/A

Eqwilate

VWD - Von Willebrand's Disease

N/A

Clinical Trials (1)

NCT04106908Effectiveness and Tolerability of Eqwilate in Real-life Conditions

N/A

Expert eCRF

Emergency Care for Severe Bleeding While on Anticoagulants

N/A

Clinical Trials (1)

NCT03320603Use of Prothrombin Complex Concentrate in Patients Admitted in Emergency Care Units for Severe Bleeding While Receiving Oral Anticoagulants

N/A

Patients using Wilate as standard of care

Von Willebrand Disease

N/A

Clinical Trials (1)

NCT01602419Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease

N/A

Gammanorm

Secondary Immune Deficiency

N/A

Clinical Trials (1)

NCT03369301The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency

N/A

Octagam IVIG 5% or 10%

Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG

N/A

Clinical Trials (1)

NCT02303093Non-Interventional Study on the Tolerability and Efficacy of IVIG

N/A

Octaplas™

Coagulopathy

N/A

Clinical Trials (1)

NCT02037373Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation

N/A

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Tre

Haemophilia A

N/A

Clinical Trials (1)

NCT03695978Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

N/A

Nuwiq

Hemophilia A

N/A

Clinical Trials (1)

NCT04023019Treatment of Hemophilia A Patients With FVIII Inhibitors

N/A

Immunoglobulins

Chronic Inflammatory Demyelinating Polyneuropathy

N/A

Clinical Trials (1)

NCT02111590Immunoglobulin Dosage and Administration Form in CIDP and MMN

N/A

Balfaxar

Vitamin K-Dependent Coagulation Defect

N/A

Clinical Trials (1)

NCT06429787Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

N/A

Cutaquig®

Primary Immune Deficiency Disorder

N/A

Clinical Trials (1)

NCT04354129Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency.

N/A

Octagam 5%

Primary Immune Deficiency Disorder

N/A

Clinical Trials (1)

NCT01859754Octagam 5% Versus Comparator Post Marketing Trial

N/A

Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of

Hemophilia A

N/A

Clinical Trials (1)

NCT02962765Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ

N/A

Fibryga

Bleeding

N/A

Clinical Trials (1)

NCT04106895Use of Fibryga, a Fibrinogen Concentrate in Real World: Retrospective Collection of Clinical Data

N/A

Von Willebrand Factor-Containing Product

Von Willebrand Diseases

N/A

Clinical Trials (1)

NCT04053699Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

N/A

ATHN 8: Previously Untreated Patients (PUPs) Matter Study

Hemophilia

N/A

Use of a postpartum diary and additional blood draws

Von Willebrand Diseases

N/A

Clinical Trials (1)

NCT04146376Von Willebrand Factor in Pregnancy (VIP) Study

N/A

Immunological diagnosis tests

Complement Deficiency

N/A

Clinical Trials (1)

NCT02972281Systematic Search for Primary Immunodeficiency in Adults With Infections

N/A

Antithrombin III

Covid19

N/A

Clinical Trials (1)

NCT04651400Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection

N/A

Fibryga

Congenital Fibrinogen Deficiency

N/A

Clinical Trials (1)

NCT03793426Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency

N/A

Wilate or Nuwiq

Hemophilia A

N/A

Clinical Trials (1)

NCT03344003Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq

N/A

octaplasLG®

Thrombotic Thrombocytopenic Purpura

N/A

Clinical Trials (1)

NCT03369314Observational Study of the Use of octaplasLG®.

N/A

Gammanorm

Autoimmune Diseases

N/A

Clinical Trials (1)

NCT03656640Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases

N/A

Octaplas LG

Comparison of Octaplas LG and Octaplas SD

PHASE_1

Clinical Trials (1)

NCT01063595A Trial to Investigate the Relative Efficacy, Safety, and Tolerability of Octaplas LG Versus Octaplas SD

Phase 1

OCTA101

Severe Hemophilia A

PHASE_1_2

Clinical Trials (1)

NCT04046848Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A

Phase 1/2

Human-cl rhFVIII

Hemophilia A

PHASE_2

Clinical Trials (1)

NCT00989196Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A

Phase 2

Placebo

Alzheimer's Disease

PHASE_2

Clinical Trials (1)

NCT00812565Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

Phase 2

Intravenously administered pooled human immunoglobulin

Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy

PHASE_2

Clinical Trials (1)

NCT06599697The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy

Phase 2

Octafibrin

Congenital Fibrinogen Deficiency

PHASE_2

Clinical Trials (1)

NCT01575756Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap

Phase 2

OctaplasLG

Septic Shock

PHASE_2

Clinical Trials (1)

NCT03092245Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock (SHOCK) Trial

Phase 2

OctaAlpha1

Alpha 1-Antitrypsin Deficiency

PHASE_2

Clinical Trials (1)

NCT03385395Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

Phase 2

Panzyga IVIG

Small Fiber Neuropathy

PHASE_2

Clinical Trials (1)

NCT04153422IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

Phase 2

NewGam 10%

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

PHASE_2_3

Clinical Trials (1)

NCT01225276Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP

Phase 2/3

Tacrolimus

Rasmussen Encephalitis

PHASE_2_3

Clinical Trials (1)

NCT00545493Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis

Phase 2/3

Octagam 10%

Immune Thrombocytopenic Purpura

PHASE_3

Clinical Trials (1)

NCT00426270Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults

Phase 3

Octafibrin

Congenital Fibrinogen Deficiency

PHASE_3

Clinical Trials (1)

NCT02408484Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency

Phase 3

Human plasma derived antithrombin

Acquired Antithrombin Deficiency

PHASE_3

Clinical Trials (1)

NCT06096116Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

Phase 3

Octaplex

Significant Bleeding Risk

PHASE_3

Clinical Trials (1)

NCT02740335Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

Phase 3

Newnorm

Primary Immune Deficiency

PHASE_3

Clinical Trials (1)

NCT04640142Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Phase 3

Human-cl rhFVIII

Severe Hemophilia A

PHASE_3

Clinical Trials (1)

NCT01992549Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

Phase 3

Octaplex

Bleeding Cardiac Surgery Patients

PHASE_3

Clinical Trials (1)

NCT05523297Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery

Phase 3

recombinant Factor VIII

Severe Hemophilia A

PHASE_3

Clinical Trials (1)

NCT01125813Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A

Phase 3

NewGam

Primary Immunodeficiency Diseases

PHASE_3

Clinical Trials (1)

NCT01012323A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases

Phase 3

octanorm 16.5%

Primary Immune Deficiency Disorder

PHASE_3

Clinical Trials (1)

NCT01888484Study of Octanorm Subcutaneous IG in Patients With PID

Phase 3

Atenativ

Congenital Antithrombin Deficiency

PHASE_3

Clinical Trials (1)

NCT04918173Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

Phase 3

Wilate

Von Willebrand Disease

PHASE_3

Clinical Trials (1)

NCT04953884Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age

Phase 3

Octanorm 16.5%

Primary Immunodeficiency

PHASE_3

Clinical Trials (1)

NCT03907241CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL

Phase 3

Octagam 10%

Dermatomyositis

PHASE_3

Clinical Trials (1)

NCT02728752Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

Phase 3

Interview Prep Quick Facts

Founded: 2020

Portfolio: 7 approved products, 89 clinical trials

Top TAs: Rare Diseases, Neurology, Infectious Diseases

Publications: 25 in PubMed

Portfolio Health

Growth1 (14%)

Peak3 (43%)

LOE Approaching3 (43%)

7 total products

Therapeutic Area Focus

Rare Diseases

1 marketed13 pipeline

Neurology

2 marketed6 pipeline

Infectious Diseases

2 marketed3 pipeline

Immunology

1 marketed4 pipeline

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Characterization of a factor VIII/immunoglobulin heavy chain μ double-knockout mouse model of hemophilia A for long-term exposure to factor VIII proteins.

Research and practice in thrombosis and haemostasis

2026

PMID:41509547

Inhalative polyclonal immunoglobulin G for the prevention of respiratory infections: A comprehensive in vitro assessment.

Octapharma

About Octapharma

Why Work Here

Key Products

Watch Out For

Products & Portfolio (7)

Key Products by Revenue

Other Products (4)

Pipeline & Clinical Trials

Open Jobs (0)

Research Publications(10)